NCT03542344已完成1 期
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Number of Participants With Drug-related Adverse Events
研究概览
简要总结
The primary objective of this trial is to investigate the safety and tolerability of BI 1015550 in healthy male subjects following oral administration of single rising doses.
Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality of BI 1015550 after single dosing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, based on a complete medical history including a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
- •Age of 20 to 45 years (incl.) at screening.
- •Body Mass Index (BMI) of 18.5 to 25.0 kg/m2 (incl.) at screening.
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation
- •Exclusion criteria:
- •Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or Electrocardiogram (ECG)) is deviating from normal and judged as clinically relevant by the investigator
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm) at screening
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance at screening
- •Any evidence of a concomitant disease judged as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders, including but not limited to mood disorders and any history of suicidality
- •History of relevant orthostatic hypotension, fainting spells, or blackouts
- •Chronic or relevant acute infections including viral hepatitis, human immunodeficiency virus (HIV) and/or syphilis. (Subject with positive Hepatitis B core antibody will not allowed to participate in this trial)
- •History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients)
- •Use of drugs within 30 days prior to administration of trial medication if that might reasonably influence the results of the trial (incl. QT/QTc interval prolongation)
- •Participation in another trial where an investigational drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug
- •Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (consumption of more 30 g per day)
- •Drug abuse or positive drug screening
- •Blood donation of more than 100 mL within 30 days prior to administration of trial medication or intended donation during the trial
- •Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms) or any other relevant ECG finding at screening
- •A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
- •Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study
- •Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until three months after the study completion.
- •Acceptable methods of contraception comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device or hormonal contraceptive since at least two months)
- •In addition, the following trial-specific exclusion criteria apply:
- •Positive or missing fecal occult blood (no retest allowed) at screening
- •Positive testing for fecal calprotectin (retest allowed) at screening
- •Positive testing for hematuria if confirmed by microscopic urine analysis (retest allowed) at screening
- •Any lifetime history of suicidal behavior (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior)
排除标准
- 未提供
研究组 & 干预措施
BI 1015550 12mg
Experimental
干预措施: BI 1015550 6 mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
BI 1015550 24mg
Experimental
干预措施: BI 1015550 6 mg (Drug)
结局指标
主要结局
Number of Participants With Drug-related Adverse Events
时间窗: From drug administration until end of study, up to 9 days
Number of participants with drug-related adverse events is presented.
次要结局
- Area Under the Concentration-time Curve of the BI 1015550 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-inf)(Within 3 hours before and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72, 96, 120 hours after drug administration.)
- Maximum Measured Concentration of the BI 1015550 in Plasma (Cmax)(Within 3 hours before and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 34, 48, 72, 96, 120 hours after drug administration.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the BloodHealthyNCT03210272Boehringer Ingelheim83
已完成
1 期
This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy MenHealthyNCT03349723Boehringer Ingelheim57
已完成
1 期
A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are ToleratedHealthyNCT04958252Boehringer Ingelheim56
已完成
1 期
First in Man Trial of BI 113608HealthyNCT01540825Boehringer Ingelheim80
已完成
1 期
A Study to Test How Healthy Men Tolerate Different Doses of BI 1595043HealthyNCT04789304Boehringer Ingelheim30